News

Explore OXB's Innovative Webinar on Viral Vector Manufacturing

Explore OXB's Innovative Webinar on Viral Vector Manufacturing

Join OXB for an Insightful Webinar on Viral Vectors

OXB, renowned for its commitment to quality and innovation in the cell and gene therapy sector, is hosting a free and informative webinar that focuses on the acceleration of viral vector drug product development using advanced robotics. This webinar promises to be a valuable opportunity for professionals interested in the future of viral vector manufacturing.

Webinar Details and Agenda

Titled "Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Release", this 60-minute session will take place on an upcoming date at a schedule that's convenient for various time zones. Attendees can expect to see how automation streamlines the production process while improving quality and efficiency.

Featured Speakers Bring Expertise

The webinar will feature leading experts from OXB, including:

  • André Raposo, PhD, Director of the Innovation Department
  • Gareth McCathie, PhD, Group Lead of the Innovation Department
  • Thomas Evans, Principal Scientist in the Innovation Department

These experts will share their insights on the pioneering automation techniques employed in viral vector manufacturing, shining a light on how digital tools are revolutionizing production processes and analytical workflows.

Focus on Innovation and Case Studies

During the presentations, attendees will be treated to case studies showcasing transfection optimization and how automated analytical methods such as qPCR, ELISA, and cell-based assays are implemented to enhance production quality. The speakers will provide real-world examples to illustrate their points, making this session particularly engaging.

Engage with Experts in Live Q&A

After the presentations, a live Q&A session will allow participants to ask questions directly to the experts, facilitating an engaging discussion about the latest trends and challenges in viral vector manufacturing.

About OXB's Legacy and Expertise

OXB (LSE: OXB) stands as a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapies. For over 25 years, OXB has been at the forefront of viral vector technology, collaborating with some of the most innovative pharmaceutical and biotechnology companies worldwide. The organization is dedicated to empowering its clients with the capabilities needed to deliver transformative therapies to patients everywhere.

OXB's extensive experience encompasses a wide array of viral vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. They pride themselves on providing robust quality-assurance systems and adhering to stringent regulatory standards, ensuring that their clients' products meet the highest benchmarks.

OXB's Cutting-Edge Technology

One notable innovation from OXB is the TetraVecta™ system, a fourth-generation lentiviral vector platform designed to enhance production capabilities. Additionally, OXB employs dual plasmid systems for AAV production, supplemented by advanced processes such as suspension and perfusion. These methodologies aim to optimize production efficiency and yield high-quality viral vectors.

Connect with OXB

As a recognized leader in the field, OXB also appreciates the importance of community engagement and ongoing dialogue. Whether industry professionals or interested parties, everyone can learn more about OXB's contributions toward advancing healthcare through innovative solutions.

For further inquiries about the webinar, interested parties can reach out directly to OXB's Chief Business Officer, Sebastien Ribault. Their contact details are available for seamless communication.

Frequently Asked Questions

What will be covered in the OXB webinar?

The webinar will focus on the use of automation in viral vector manufacturing processes and include case studies demonstrating its real-world applications.

Who are the speakers at the webinar?

Expert speakers from OXB's Innovation Department will present, sharing their vast knowledge and experiences in viral vector manufacturing.

How can I register for the webinar?

Participants can register for the webinar through OXB's official website or the provided registration link.

What are the benefits of attending this webinar?

Attendees will gain insights into the latest technological advancements in viral vector manufacturing and have the opportunity to engage with industry experts.

Is there a cost associated with the webinar?

No, the webinar is free to attend, making it accessible for all interested professionals.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 102

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 76

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 72

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Seasonal Hiring Booms as Firms Eye Long-Term Talent

Updated Category News Views 327

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Continue Reading
Nebius Secures $700 Million to Accelerate AI Infrastructure Growth

Updated Category News Views 269

Nebius Secures $700 Million to Accelerate AI Infrastructure Growth Nebius Group N.V. (“Nebius Group”, “Nebius” or the “Company”; NASDAQ:NBIS), a prominent player in AI infrastructure, has made an exciting announcement regarding a substantial private placement financing. In a strategic move to bolster its operations, the company has secured USD 700 million from...

Continue Reading
Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO

Updated Category News Views 183

Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company specializing in neuroscience, has made a significant move by appointing Tucker Kelly as the new Chief Financial Officer (CFO). This decision signals the company's commitment to strategic financial management as it gears up for the commercialization of...

Continue Reading
Brookfield Makes Big Moves in Japan's Real Estate Market

Updated Category News Views 302

Brookfield's Bold Ventures into Japan's Real Estate Landscape Canadian investment firm Brookfield Asset Management (TSX: BAM) has recently made headlines with its significant real estate endeavors in Japan, closing two major deals that amount to a staggering $1.6 billion. The Significant Investments Overview The recent acquisitions involve a noteworthy stake in the iconic...

Continue Reading
Pacira BioSciences Facing Legal Challenges and Investor Updates

Updated Category News Views 170

Legal Proceedings Impacting Pacira BioSciences, Inc. Shareholders of Pacira BioSciences, Inc. should be aware of a significant class action lawsuit that is currently unfolding. This lawsuit, noted for its complexity, aims to address allegations of securities fraud impacting investors. The firm representing the investors, is Levi & Korsinsky, a well-established legal group...

Continue Reading